SequelSEC

CASTLE BIOSCIENCES INC CSTL

Services-Medical Laboratories · CIK 0001447362 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$344.23M
Fiscal year ended 2025-12-31
Operating income
-$42.81M
Fiscal year ended 2025-12-31
Free cash flow
$28.33M
Fiscal year ended 2025-12-31

CASTLE BIOSCIENCES INC (CSTL) reported revenue of $344.23M and net income of -$24.16M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from CASTLE BIOSCIENCES INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

CASTLE BIOSCIENCES INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$344.23M$332.07M$219.79M$137.04M$94.08M$62.65M$51.86M$22.79M
Cost of revenue$71.03M$60.20M$44.98M$32.01M$15.82M$9.68M$7.31M$5.30M
Gross profit$273.20M$271.86M$174.81M$105.03M$78.26M$52.96M$44.56M$17.49M
Operating income-$42.81M$8.67M-$67.98M-$72.86M-$40.08M-$6.54M$7.33M-$3.84M
Net income-$24.16M$18.24M-$57.47M-$67.14M-$31.29M-$10.28M$5.28M-$6.37M
Research & development$51.85M$52.04M$53.62M$44.90M$29.65M$13.26M$7.38M$4.85M
Weighted-average diluted sharesshares 28.99Mshares 29.26Mshares 26.80Mshares 26.05Mshares 25.14Mshares 18.93Mshares 8.66Mshares 1.91M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense-$5.36M$3.32M$101.00K-$1.77M-$8.72M$84.00K$72.00K$9.00K
Diluted EPS$-0.83$0.62$-2.14$-2.58$-1.24$-0.54$-0.21$-5.33
Selling, general & administrative$229.32M$200.05M$180.15M$143.00M$86.74M$48.13M$29.84M$16.47M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

CASTLE BIOSCIENCES INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$116.73M$119.71M$98.84M$122.95M$329.63M$409.85M$98.84M$4.48M
Total assets$578.56M$531.24M$453.34M$447.33M$462.57M$439.33M$119.75M$22.40M
Current assets$361.10M$360.15M$295.64M$292.29M$353.74M$429.59M$116.68M$18.13M
Total liabilities$107.68M$75.40M$62.07M$48.18M$50.83M$23.64M$34.63M$32.48M
Current liabilities$68.68M$49.39M$47.67M$36.13M$24.89M$20.88M$15.29M$6.74M
Total equity incl. NCI$470.87M$455.84M$391.27M$399.15M$411.74M$415.69M$85.11M-$56.57M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$10.25M$8.14M$7.94M$3.98M$2.02M$2.22M$1.24M$882.00K
Accounts receivable$43.38M$51.22M$38.30M$23.48M$17.28M$12.76M$14.65M$12.09M
Goodwill$10.70M$10.70M$10.70M$10.70M$0UnavailableUnavailableUnavailable
Long-term debt$9.64M$9.74M$0UnavailableUnavailable$0$19.29M$24.50M
Accounts payable$18.71M$6.90M$10.27M$4.73M$2.55M$2.10M$1.86M$1.45M

Cash flow

CASTLE BIOSCIENCES INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow$64.35M$64.87M-$5.63M-$41.66M-$18.98M$9.86M$7.02M-$12.30M
Capital expenditures$36.02M$28.33M$13.62M$5.63M$3.48M$4.75M$937.00K$277.00K
Investing cash flow-$60.37M-$50.14M-$16.18M-$166.54M-$66.66M-$4.75M-$937.00K-$277.00K
Financing cash flow-$6.96M$6.14M-$2.30M$1.52M$5.42M$305.89M$88.29M$15.84M
Net change in cash-$2.98M$20.87M-$24.11M-$206.68M-$80.22M$311.01M$94.37M$3.27M
Stock-based compensation$45.89M$50.32M$51.22M$36.32M$21.74M$8.31M$1.25M$294.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$40.77M$16.00M$12.33M$10.54M$3.41M$472.00KUnavailableUnavailable

Derived

CASTLE BIOSCIENCES INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flow$28.33M$36.54M-$19.25M-$47.29M-$22.47M$5.11M$6.08M-$12.57M
Gross margin79.4%81.9%79.5%76.6%83.2%Unavailable85.9%76.8%
Operating margin-12.4%2.6%-30.9%-53.2%-42.6%-10.4%14.1%-16.8%
FCF margin8.2%11.0%-8.8%-34.5%-23.9%8.2%11.7%-55.2%
SBC / revenue13.3%15.2%23.3%26.5%23.1%13.3%2.4%1.3%
Current ratio5.26x7.29x6.20x8.09x14.21x20.58x7.63x2.69x
Revenue YoY growth3.7%51.1%60.4%45.7%50.2%20.8%127.6%Unavailable
Net margin-7.0%5.5%-26.1%-49.0%-33.3%-16.4%10.2%-27.9%
R&D / revenue15.1%15.7%24.4%32.8%31.5%21.2%14.2%21.3%
CapEx / revenue10.5%8.5%6.2%4.1%3.7%7.6%1.8%1.2%
Long-term debt / equity0.02xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CSTL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

ACON ADVB AMS BDSX BGLC BLLN CAI CDNA CELC CFOR DGX FCHS

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2018-12-31

Difference 46496000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.